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To commemorate the 100th anniversary of the Nobel prize being awarded to Jules Bordet, the discoverer of Bordetella pertussis, the 
12th International Bordetella Symposium was held from 9 to 12 April 2019 at the Université Libre de Bruxelles, where Jules Bordet 
studied and was Professor of Microbiology. The symposium attracted more than 300 Bordetella experts from 34 countries. They dis-
cussed the latest epidemiologic data and clinical aspects of pertussis, Bordetella biology and pathogenesis, immunology and vaccine 
development, and genomics and evolution. Advanced technological and methodological tools provided novel insights into the ge-
nomic diversity of Bordetella and a better understanding of pertussis disease and vaccine performance. New molecular approaches 
revealed previously unrecognized complexity of virulence gene regulation. Innovative insights into the immune responses to infec-
tion by Bordetella resulted in the development of new vaccine candidates. Such discoveries will aid in the design of more effective 
approaches to control pertussis and other Bordetella-related diseases.
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The 1919 Nobel prize in Physiology/Medicine was awarded to 
Jules Bordet for his discovery of alexine, today referred to as 
complement. However, to the Bordetella community he is prob-
ably best known for the identification of the whooping cough 
agent, initially named Haemophilus pertussis and now known 
as Bordetella pertussis. In honor of Jules Bordet and to com-
memorate his Nobel Prize, the 12th International Bordetella 
Symposium was held from 9 to 12 April 2019, at the Université 
Libre de Bruxelles, where he studied and spent most of his 
scientific career.
OPENING SESSION
Several grandchildren and great-grandchildren of Jules 
Bordet were present during the opening session, and 
Bordet’s great-granddaughter Nathalie Devroey presented 
a portrait of her great-grandfather with focus on his gen-
erous and warm personality. She explained how he intro-
duced his grandchildren to scientific discovery and to 
classic literature, and how “he had the most marvelous 
ability to explain the most complicated things in the most 
understandable ways.”
James D. Cherry delivered the opening lecture on the 112-
year odyssey of pertussis and pertussis vaccines. He high-
lighted the various misconceptions and their consequences 
for the current pertussis problem. Although on the rise in 
several countries, the rate of pertussis today is approximately 
20-fold less than in the prevaccine era [1]. Furthermore, 
vaccine failures result in less severe illness than seen in un-
vaccinated children. Pertussis occurs in cycles of 2–5 years, 
which has not significantly changed since the introduction 
of pertussis vaccines, indicating that vaccination does not 
impede B.  pertussis circulation. Asymptomatic infections, 
a major finding in children, are 4–22 times more common 
than symptomatic infections. Pertussis toxin (PT) is a major 
virulence factor in clinical disease [2], and an as yet uniden-
tified “cough toxin” may participate in the clinical picture 
of pertussis. Finally, he discussed reasons why acellular per-
tussis (aP) vaccines are inferior to whole-cell (wP) vaccines, 
including linked-epitope suppression, genetic changes in-
duced by aP vaccines, a suboptimal balance of antigens, 
and failure to induce the appropriate T-cell subtypes. Thus, 
new pertussis vaccines are needed, either multicomponent 
aP vaccines with appropriate adjuvants, less reactogenic wP 
vaccines, or live attenuated vaccines.
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SPECIAL SESSION ON ADENYLATE CYCLASE TOXIN
A special session was organized as a tribute to the lifetime 
achievements of Erik Hewlett, who made seminal contributions 
to understanding the role of adenylate cyclase toxin (ACT) and 
played a key role in the initiation and organization of many of 
the previous International Bordetella Symposia and in fostering 
the constitution of the International Bordetella Society.
F. Heath Damron summarized Hewlett’s career, from his col-
lege training in Fulton, Missouri in 1968, to his full professor-
ship at the University of Virginia. He also highlighted Hewlett’s 
scientific contributions to the understanding of the ACT bi-
ology and the enhanced protective effect of adding ACT to aP 
vaccines [3].
Erik Hewlett followed by presenting the history of ACT. A col-
laboration between Hewlett, Jan Wolff, and Charles Manclark 
led to the discovery of a 70-kDa extracytoplasmic adenylate cy-
clase lacking toxin activity [4], which was subsequently shown 
to be a fragment of the much larger ACT secreted by B.  per-
tussis. His team demonstrated that ACT secretion and folding 
requires calcium, that the expression of its enzymatic activity 
requires calmodulin, and that ACT interacts with filamentous 
hemagglutinin and inhibits biofilm formation [5].
Daniel Ladant delivered a lecture in honor of Agnès Ullmann, 
who had passed away a few months earlier, at the age of 92. He 
summarized her major contributions on ACT, including the pu-
rification of full-length ACT, the cloning and sequencing of its 
structural gene cyaA, and the deciphering of the cya locus ge-
netic organization and transcriptional regulation [6]. He then 
presented the use of ACT as antigen-delivery vehicle and pro-
vided examples of ACT-grafted antigens delivered into the cy-
tosol of antigen-presenting cells [7]. He also illustrated the use 
of ACT as a tool for the study of protein–protein interactions 
[8]. Finally, he presented a model for ACT translocation into 
target cells and activation of the enzyme by calmodulin [9].
Peter Sebo illustrated the multiple and sometimes unex-
pected biological activities of ACT. He showed how calcium 
drives the formation of an intramolecular Brownian ratchet that 
directs unfolded ACT through the secretion system, and how 
ACT interacts with CD11b/CD18 on myeloid phagocytes and 
is then translocated. ACT blocked phagocytosis and oxidative 
burst, suppressed Toll-like receptor (TLR) signaling, induced 
apoptosis, and reprogrammed tolerogenic dendritic cells and 
macrophages [10, 11].
CLINICAL AND EPIDEMIOLOGICAL ASPECTS OF 
PERTUSSIS
Nicola Klein presented data on the epidemiology of pertussis in 
children and adolescents and noted the rapid loss of effective-
ness of the reduced antigen aP vaccine in preadolescents over a 
3-year period.
A human challenge model of B.  pertussis colonization was 
presented by Robert Read. He described a dose-finding study 
and found that the dose necessary to achieve 80% colonization 
was 105 colony-forming units, and that colonization peaked at 
day 11 and was associated with serum anti–B.  pertussis anti-
body titer rises [12].
Helen Campbell presented an update on the national per-
tussis immunization program of pregnant women in England 
and assessed vaccine effectiveness (VE). Vaccine coverage was 
72% in 2017–2018, and VE in infants ≤ 2 months of age was 90% 
to 97% against fatal infant pertussis. The VE of 5-component 
aP vaccine was greater than that of 3-component aP vaccine. 
Using hospital-based surveillance in Australia, Helen Marshall 
reported 85% VE of maternal immunization for infants aged 
≤ 2 months and 70% VE for infants ≤ 6 months. Among 183 in-
fants suffering from pertussis, 16% required intensive care, 6% 
required assisted ventilation, and 1 infant died.
Matt Edmunds presented a retrospective South England sec-
ondary boarding school cohort study and showed that 30% 
had culture-confirmed, probable, or possible pertussis; 12% 
had asymptomatic infections; and 6% were asymptomatic car-
riers. The overall attack rate was 48%. However, nonreporting 
was a problem, and he suggested that aP vaccination should be 
used in outbreak situations and routine adolescent aP boosters 
should be considered.
René Raeven compared anti-PT immunoglobulin G (IgG) 
values and immunoproteomic profiles of B. pertussis infection–
induced responses between humans with different pertussis 
immunization backgrounds (aP vs wP). He used multiplex im-
munoassays, 1- and 2-dimensional immunoblotting, and mass 
spectrometry, both to the usual B.  pertussis antigens and to 
outer membrane vesicles (OMVs), and noted that the antibody 
patterns were different among the groups receiving different 
pertussis vaccines.
Norman Fry commented on external quality assessment for 
the detection of B. pertussis by polymerase chain reaction (PCR) 
in Europe. Investigators from Sweden, Finland, and England 
evaluated different PCR methods and compared results at 
2 different times, from 28 different European laboratories. They 
demonstrated substantial improvement from the first to the 
second survey.
BORDETELLA BIOLOGY AND PATHOGENESIS
New information was provided on gene regulation in Bordetella, 
including new data on regulation by the 2-component systems 
BvgAS and RisAK [13], and by small noncoding RNA. In the 
virulent phase, the B. pertussis BvgAS system is activated, and 
expression of virulence-activated genes increases. In contrast, 
their expression decreases in the avirulent phase when B. per-
tussis expresses virulence-repressed genes (vrgs). The expres-
sion of these genes depends on the transcription factor RisA, 
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which is phosphorylated by the histidine kinase RisK. Qing 
Chen investigated whether RisR, whose gene is co-transcribed 
with risK, may also participate in vrg regulation. A risR deletion 
was lethal in the Bvg− phase. Under Bvg− conditions, the risR 
mutant grew only in the presence of suppressor mutations that 
resulted in a phase-locked Bvg+ phenotype or mutations that 
reduced RisA levels. A  risA/risR mutant rescued the lethality 
of the risR mutation. Whereas the RisA histidine kinase RisS is 
inactive in B. pertussis, it is intact in Bordetella bronchiseptica 
and functions as a phosphatase. Alterations of threonine 262 
converted it to a kinase and induced a mucoid phenotype due 
to the expression of capsular polysaccharide genes.
Gyles Ifill generated an RNAase III active site mutant and an 
RNase E C-terminal deletion, and observed that half of the dif-
ferentially expressed genes in the mutants were also found in 
the transcriptome of an hfq mutant published previously [14]. 
Regulatory RNAs may modulate virulence, as approximately 
50% of the differentially expressed genes in the RNase mutants 
were BvgAS regulated.
Tod Merkel showed that the baboon B.  pertussis challenge 
model recapitulates the characteristic signs of human pertussis, 
including leukocytosis, paroxysmal coughing, mucus produc-
tion, and B.  pertussis transmission [15]. It also showed more 
severe disease in younger than in older animals. However, un-
like in young humans, there was no significant pathology in the 
trachea of baboons. RisA-deficient B. pertussis grew well in ba-
boons but was impaired in transmission, indicating that vrgs 
participated in B. pertussis transmission. Thibaut Naninck fol-
lowed B. pertussis colonization of the baboon respiratory tract 
over time by probe-based confocal laser endomicroscopy using 
green fluorescent protein–expressing bacteria. He could quan-
tify bacterial colonization and observe interactions of the bac-
teria with antigen-presenting cells in trachea and bronchi.
Using an infant mouse model, Karen Scanlon elucidated 
the role of PT in the development of severe pertussis. PT 
activated the pulmonary angiotensin (AT) system and in-
hibited the protective AT2 functions in infant mice, even-
tually leading to pulmonary hypertension. She also showed 
that angiotensin-converting enzyme inhibitors might be 
useful to improve disease outcome. Katharina Ernst showed 
that host cell cyclophilin isoforms CypA and Cyp40 are re-
quired for translocation of the PT S1 subunit into the cy-
tosol, which might make them a target for novel therapeutic 
strategies against pertussis.
Françoise Jacob-Dubuisson presented studies on B. pertussis 
homeostasis of copper, a metal that is both essential and toxic 
for living organisms. Unlike for other pathogens, copper export 
or detoxification systems are absent or not copper-regulated 
in B.  pertussis. In excess copper, only a cytoplasmic copper 
chaperone was induced. Under copper starvation, B. pertussis 
upregulated an operon coding for a putative TonB-dependent 
transporter and 2 proteins of unknown functions. Thus, 
B. pertussis copper homeostasis is more focused on harvesting 
the metal than defending from its toxicity.
Iain MacArthur reported that the B.  pertussis growth inhi-
bition by hydrophobic molecules [16] is due to alterations of 
the Acr system, an export system of acriflavine and other small 
hydrophobic molecules. Mutations in acr are conserved in 
B.  pertussis, suggesting a selective advantage for these muta-
tions. However, neither Bordetella parapertussis nor Bordetella 
holmesii, also human pathogens, have these mutations. The se-
lective advantage in becoming more sensitive to hydrophobic 
molecules thus remains an open question.
IMMUNITY AND VACCINATION
Kingston Mills demonstrated that B.  pertussis infection in-
duces interleukin 17 (IL-17)– and interferon gamma (IFN-
γ)−secreting tissue-resident memory T cells (TRM) in the nose 
and lungs of mice [17], which proliferate after reinfection, 
mediating rapid pathogen clearance. wP vaccines also primed 
TRM, whereas aP vaccines did not and failed to protect against 
nasal colonization. An aP vaccine with a TLR2 agonist and c-di-
GMP adjuvant instead of alum induced TRM cells and opson-
izing antibodies. Using PT-deficient B. pertussis strains, Cyrille 
Mionnet found that PT was required to generate mouse lung 
CD4+, CD8+, and γδ TRM cells. Coadministration of PT with 
the PT-deficient strain restored the generation of TRM cells. 
Adoptive transfer of TRM cells protected mice against B.  per-
tussis infection.
Jeremy Ardanuy found that the type I  and III interferon 
(IFN) receptors are important activators of inflammatory re-
sponses in B. pertussis–infected mice. Type I and III IFNs were 
produced in the lungs 4 days postinoculation and peaked at day 
10. Infected type I  IFN receptor knockout mice had lung pa-
thology levels similar to those of wild-type mice because of in-
creased levels of type III IFN.
Monica Cartelle Gestal identified a putative regulator, BtrS 
[18], implicated in the control of immunomodulation. BtrS 
was involved in survival within macrophages, inflammasome 
activation, suppression of immune cell recruitment, and per-
sistence in the respiratory tract. Infection with a btrS mutant 
induced robust immunity against reinfection with all classical 
Bordetella.
Michel Kroes demonstrated that activation of human NK 
cells by B.  pertussis is secondary to inflammasome activation 
and interleukin 18 secretion by macrophages. NK cells then se-
creted IFN-γ, which enhanced antimicrobial activity of macro-
phages and participated in Th1 skewing.
Ricardo da Silva Antunes compared T-cell responses in-
duced after aP boosting of adults vaccinated as infants with 
aP vs wP vaccines [19]. T cells remained polarized as a func-
tion of their original priming. The capacity of memory CD4+ T 
cells to expand after boosting was only observed in wP-primed 
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individuals. Priming by either vaccine was associated with in-
creased antibody titers and plasmablasts after boosting, sug-
gesting that waning immunity is T-cell specific rather than 
B-cell specific.
Parul Kapil examined whether aP-primed Th2 responses 
could be polarized towards Th1 and Th17 responses in ba-
boons after B.  pertussis infection and found that infection of 
the aP-primed animals induced Th17 and Th2, but no Th1 re-
sponses. Following a second challenge with B. pertussis, unvac-
cinated convalescent animals were protected from colonization, 
while aP-vaccinated convalescent animals were not.
Bahaa Abu-Raya showed that maternal immunization during 
pregnancy interfered with the infant’s antibody production. 
This was noted both after primary vaccination and after booster 
doses, and was also seen for antibody titers against diphtheria 
toxin and pneumococcal polysaccharides, but not for anti– 
tetanus toxin responses.
Dylan Boehm compared nasal diphtheria, tetanus, and acel-
lular pertussis (DTaP) and DTaP plus curdlan administration in 
mice and found that in the absence of curdlan, DTaP accumu-
lated in the lungs, whereas in its presence, DTaP was retained 
in the nasal cavity. Intranasal immunization with either vaccine 
decreased the bacterial burden in the lungs and induced sys-
temic anti-PT IgG responses together with inhibition of leu-
kocytosis after B. pertussis infection. Immunoglobulin A (IgA) 
was detected in nasal lavages, especially following immuniza-
tion with DTaP plus curdlan.
Camille Locht explained the rationale for the live attenuated 
nasal pertussis vaccine BPZE1 [20]. BPZE1 protected against 
lung and nasal B. pertussis colonization in mice and baboons. 
Protection depended on secretory IgA and IL-17–secreting TRM 
cells [21]. Clinical trials in humans were performed that dem-
onstrated safety of the vaccine and up to 100% seroconversion.
Ang Lin showed that plasmablasts and Th1-type follic-
ular T lymphocytes appeared in BPZE1-vaccinated volun-
teers 4–14  days after vaccination, as well as BPZE1-specific 
Th1-polarized T cells. All BPZE1 recipients developed spe-
cific memory B cells and anti-BPZE1 IgG and IgA titers. 
Antigen specificity of these antibodies was broader than that 
of aP-vaccinated subjects and was predominantly directed to 
antigens not present in aP vaccines.
Daniela Hozbor illustrated that Bordetella OMVs [22] in-
duced superior immunity in mice than aP vaccination. 
Maternal immunization did not inhibit OMV-induced immu-
nity. Bordetella parapertussis and B. bronchiseptica OMVs pro-
tected against the respective pathogens. Protection depended 
on lipopolysaccharide O antigen and was also seen with OMVs 
from bacteria in the avirulent phase.
Jennifer Maynard demonstrated that humanized anti-PT 
monoclonal antibody hu1B7 [23] provided protection against 
pertussis in pertussis-challenged neonatal baboons by inhibiting 
intracellular PT trafficking. A modified version of hu1B7 with 
extended half-life was also protective, and white blood cell 
levels in infected baboons were inversely correlated with hu1B7 
levels, which may help in defining minimum protective titers.
EVOLUTIONARY AND GENOMIC ASPECTS OF 
BORDETELLA
Michael Weigand presented novel approaches to analyze ge-
nome diversity including >3500 coding regions of B. pertussis. 
Whole-genome multiple locus sequence typing could also be 
directly applied on nasopharyngeal specimens.
Andrew Preston revealed that intragenomic recombi-
nation between insertion sequences caused genomic rear-
rangement and that different genome orders exist among 
B.  pertussis isolates [24]. Insertion sequence–mediated 
recombination can result in duplication, with 12 such du-
plications described. They can be highly unstable [25, 26]. 
Among 2430 B.  pertussis isolates analyzed, 191 contained 
duplications, 94% of which were in 11 “hotspot” loci.
Pertussis has been treated with macrolides for dec-
ades, and Qiushui He explained that macrolide-resistant 
isolates are now found in China [27], as well as spo-
radically in Europe [28], the Middle East [29] and the 
United States [30]. Resistance was generally attributed 
to a A2047G mutation in the domain V of the 23S ri-
bosomal RNA gene. The frequency of this mutation in-
creased in China and is currently at 60%–92%.
By harnessing whole-population and age-stratified inci-
dence data, genomic, and demographic data and vaccine cov-
erage, Ana Bento and Pejman Rohani formulated evolutionary 
models of B. pertussis history and transmission dynamics. They 
concluded that there was a positive association between genetic 
diversity and pertussis disease incidence, suggesting that the re-
surgence is associated with the expansion of strains that cause 
more detectable symptoms.
BORDETELLA OTHER THAN BORDETELLA 
PERTUSSIS
Eric Harvill discussed Bordetella phylogenetics. He highlighted ev-
idence for an environmental origin of the genus, leading to 2 inde-
pendent but intersecting transmission cycles for B. bronchiseptica, 1 
circulating as a respiratory pathogen in mammals and 1 as an asso-
ciation between the bacteria and predatory amoeba. As amoeba can 
colonize mammalian hosts, he speculated that B. bronchiseptica can 
switch between those 2 life cycles [31]. Interactions with amoeba may 
also represent the starting point for bacterial adaptation to eukary-
otic cells. B. pertussis evolution toward a closed human-to-human 
lifecycle has involved genome reduction and the loss of ability to uti-
lize amoeba as reservoir.
Tracy Nicholson characterized the B.  bronchiseptica BvgR 
and RisAS regulons by using various isogenic mutants and 
measuring transcriptional responses of each mutant under 
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modulating and nonmodulating growth conditions. This re-
vealed a previously unrecognized complex regulation of viru-
lence pathways in B. bronchiseptica.
Kacey Yount demonstrated that Bordetella coloniza-
tion factor A (BcfA) [32], used as an adjuvant, enhanced 
immune responses to B.  bronchiseptica and B.  pertussis 
antigens. Vaccines formulated with BcfA induced pro-
tection against B.  bronchiseptica in mice. With BcfA-
containing formulations, the Th2 responses elicited by 
Bordetella immunogens were attenuated, resulting in 
Th1/Th17 polarized responses.
CONCLUSIONS
Since the 11th International Bordetella Symposium in 
2016 [33], the Bordetella research community has grown 
substantially, and the 12th symposium gathered more 
delegates than ever before.
New, up-to-date technologies were applied to further our 
understanding and revise some of the previous assumptions 
about Bordetella biology, genomics, immunology, and vac-
cine development. The baboon challenge model for pertussis 
was implemented in several laboratories and helped to refine 
our knowledge on B. pertussis infection and vaccine-induced 
immunity. Particularly exciting was the establishment of a 
controlled human challenge model for pertussis, which may 
be helpful to determine correlates of protection and to test 
novel pertussis vaccines. These advances provide hope for 
improved control of Bordetella infections. It will be inter-
esting to see how these developments have evolved at the 13th 
International Bordetella symposium, scheduled for 2022 in 
Vancouver, Canada.
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